Ocuphire Pharma Investor Presentation Deck

11 Additional VEGA-1 Phase 2 Efficacy Results Nyxol + LDP Efficacy Data has Potential for Differentiation ● Met the planned Phase 3 primary endpoint of 15 letters (3 lines) near vision gain with less than 5 letters of distance vision loss Statistical significance and/or trend across multiple timepoints for combination treatment vs. each individual component (Nyxol or LDP) • Met multiple additional key secondary endpoints Nyxol+LDP was numerically better than each component at every timepoint Efficacy data in both light and dark iris colors Near vision efficacy seen monocularly - - Source: VEGA-1 Clinical Study Results Ocuphire PHARMA

View entire presentation